Scarica l'app Stockscreener
2.12
6.00%
0.12
Dopo l'orario di chiusura:
2.09
-0.03
-1.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.00
Aprire:
$2
Volume 24 ore:
5.34M
Relative Volume:
1.53
Capitalizzazione di mercato:
$398.81M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.7518
EPS:
-2.82
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+1.92%
1M Prestazione:
-1.85%
6M Prestazione:
+1.92%
1 anno Prestazione:
+105.83%
Intervallo 1D:
$1.965
$2.14
Intervallo di 1 settimana:
$1.965
$2.195
Portata 52W:
$0.865
$3.40
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire
Esperion Announces a Featured Presentation in the Late - GlobeNewswire
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance
Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat
Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexletol From Esperion - Pharmacy Times
Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com
Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com - MarketBeat
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst - MarketBeat
Esperion shares reiterate Buy rating on trial data By Investing.com - Investing.com South Africa
Esperion shares reiterate Buy rating on trial data - Investing.com India
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Insider Monkey
Esperion reports LDL-C reduction success in MILOS study By Investing.com - Investing.com South Africa
Esperion reports LDL-C reduction success in MILOS study - Investing.com
Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - The Manila Times
Esperion EU Partner Reports Final Real-World Results from - GlobeNewswire
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat
Marshall Wace LLP Raises Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Esperion Therapeutics (NASDAQ:ESPR) Lowered to Hold at StockNews.com - MarketBeat
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily
ESH Acquisition Corp. (NASDAQ:ESHA) Shares Bought by Berkley W R Corp - Defense World
What's Going On With Seelos Therapeutics Stock Tuesday? - Benzinga
Great Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Great Point Partners LLC - MarketBeat
New Pill Cuts Cholesterol and Heart Attacks - Greek Reporter
What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News
Atopic dermatitis: New drug significantly improves symptoms - Medical News Today
How does ESAB Corp (ESAB) change from a tortoise to a hare? - SETE News
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd - Defense World
XTX Topco Ltd Has $810,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Espey Mfg. & Electronics (NYSEAMERICAN:ESP) Receives New Coverage from Analysts at StockNews.com - Defense World
Inspire Investing LLC Invests $758,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESAB Co. (NYSE:ESAB) Shares Sold by Granite Investment Partners LLC - Defense World
Bank of New York Mellon Corp Acquires 555,382 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
18,727 Shares in ESAB Co. (NYSE:ESAB) Bought by Seven Eight Capital LP - Defense World
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):